Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

Urology

Volumn 49, Issue 3, 1997, Pages 379-384

  Carter, H Ballentine ^a   Partin, Alan W ^b   Luderer, Albert A ^b   Metter, E Jeffrey ^b   Landis, Patricia ^b   Chan, Daniel W ^b   Fozard, James L ^b   Pearson, Jay D ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0030933344     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00629-2     Document Type: Article

References (17)

1. Gann PH, Hennekens CH, and Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289-294, 1995.
2. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
3. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
4. Lilja H, Christensson A, Dahlen U, Matikainen M, Nilsson O, Petterson K, and Lovgren T: Prostate-specific antigen in human serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
5. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
6. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
7. Pearson JD, Partin AW, Chan DW, Luderer AA, and Carter HB: Serial measurements of serum total PSA, free PSA, and free/total PSA ratio in men with and without prostate disease (abstract 1179). J Urol 155: 606A, 1996.
8. Carter HB, Pearson JD, Metter JE, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
9. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT Jr, Lakatta EG, and Tobin JD: Normal Human Aging: The Baltimore Longitudinal Study of Aging (NIH publication No. 84-2450). Washington, DC: US Government Printing Office, 1984.
10. Lindstrom MJ, and Bates DM: Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc 83: 1014-1022, 1988.
11. Leinonen J, Lovgren T, Vornanen T, and Stenman UH: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha-1-antichymotrypsin. Clin Chem 39: 2098-2103, 1993.
12. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett ATK, Abrahamsson P-E, and Lilja H: Serum prostate-specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
13. 1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 42: 502-510, 1993.
14. 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43: 427-434, 1994.
15. Partin AW, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, and Luderer AA: Free/total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer (abstract 419). J Urol 155: 415A, 1996.
16. Lerner SE, Jacobsen SJ, Bergstralh EJ, Klee GG, Blute ML, Lieber MM, Zincke H, Lilja H, and Oesterling JE: Free, complexed, and total serum PSA concentrations and their proportions in predicting stage, grade, and DNA ploidy in patients with prostate cancer (abstract 421). J Urol 155: 416A, 1996.
17. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, and Catalona WJ: Correlation of percent free PSA with pathologic features of prostatic carcinomas (abstract 420). J Urol 155: 415A, 1996.